Keyphrases
Pathophysiology
100%
Chronic Spontaneous Urticaria
100%
Monoclonal Antibody
28%
Recurring
14%
New Therapeutics
14%
Orally Administered
14%
Novel Therapies
14%
Clinical Prognosis
14%
Targeted Therapy
14%
Pediatric Patients
14%
Adult Patients
14%
Randomized Controlled Trial
14%
Benralizumab
14%
Wheals
14%
Urticaria
14%
Point Prevalence Survey
14%
H1-antihistamines
14%
Omalizumab
14%
Self-limited Disease
14%
Quality of Life Impact
14%
Dupilumab
14%
New Trial
14%
Scoping Literature Review
14%
Ligelizumab
14%
Bruton Tyrosine Kinase Inhibitor
14%
Medicine and Dentistry
Pathophysiology
100%
Chronic Urticaria
100%
Monoclonal Antibody
28%
Urticaria
28%
Disease
14%
Prevalence
14%
Quality of Life
14%
Targeted Therapy
14%
Pediatrics Patient
14%
Randomized Controlled Trial
14%
Omalizumab
14%
H1 Antagonist
14%
Dupilumab
14%
Benralizumab
14%
Ligelizumab
14%
Bruton Tyrosine Kinase Inhibitor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Pathophysiology
100%
Chronic Urticaria
100%
Monoclonal Antibody
28%
Urticaria
28%
Disease
14%
Prevalence
14%
Randomized Controlled Trial
14%
Benralizumab
14%
Histamine H1 Receptor Antagonist
14%
Omalizumab
14%
Dupilumab
14%
Ligelizumab
14%
Bruton Tyrosine Kinase Inhibitor
14%
Immunology and Microbiology
Chronic Urticaria
100%
Monoclonal Antibody
28%
Prevalence
14%
Omalizumab
14%
Histamine H1 Receptor Antagonist
14%
Benralizumab
14%
Dupilumab
14%
Bruton Tyrosine Kinase
14%
Ligelizumab
14%